Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PDE8A | O60658 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667447 | 0.88 | HPGD (0.51) | HPGDNR3C1ADORA2AMEN1KMT2A | |
| SCHEMBL20774516 | 0.84 | HPGD (0.54) | HPGDNR3C1ADORA2AMEN1KMT2A | |
| SCHEMBL30552245 | 0.84 | HPGD (0.54) | HPGDNR3C1ADORA2AMEN1KMT2A | |
| SCHEMBL6948922 | 0.77 | CNR2 (0.46) | HPGDNR3C1ADORA2AMEN1KMT2A | |
| SCHEMBL6952432 | 0.77 | MEN1 (0.52) | HPGDNR3C1ADORA2AMEN1KMT2A | |
| SCHEMBL6952351 | 0.76 | HPGD (0.49) | HPGDNR3C1ADORA2AMEN1KMT2A | |
| SCHEMBL5465357 | 0.76 | HPGD (0.64) | HPGDNR3C1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3642511 | 0.75 | HPGD (0.62) | HPGDNR3C1ADORA2AMEN1KMT2A | |
| SCHEMBL1422156 | 0.75 | NSD3 (0.70) | HPGDADORA2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL5134079 | 0.74 | HPGD (0.39) | HPGDNR3C1ADORA2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8518943-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518943-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-08-27 | — | — | US | disclosed |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | disclosed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| EP-2308867-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | HPGD 172/4885NR3C1 2469/4885ADORA2A 620/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | HPGD 172/4885NR3C1 2469/4885ADORA2A 620/4885 |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | HPGD 172/4885NR3C1 2469/4885ADORA2A 620/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | HPGD 147/4885NR3C1 1377/4885ADORA2A 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.